BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 24606093)

  • 21. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
    Genazzani AD; Battaglia C; Malavasi B; Strucchi C; Tortolani F; Gamba O
    Fertil Steril; 2004 Jan; 81(1):114-9. PubMed ID: 14711553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
    Berker B; Emral R; Demirel C; Corapcioglu D; Unlu C; Kose K
    Gynecol Endocrinol; 2004 Sep; 19(3):125-33. PubMed ID: 15697073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
    Morin-Papunen LC; Koivunen RM; Ruokonen A; Martikainen HK
    Fertil Steril; 1998 Apr; 69(4):691-6. PubMed ID: 9548159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.
    Koivunen RM; Morin-Papunen LC; Ruokonen A; Tapanainen JS; Martikainen HK
    Hum Reprod; 2001 Dec; 16(12):2546-51. PubMed ID: 11726572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A; Agarwal N
    J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
    Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
    Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin therapy in women with polycystic ovary syndrome.
    Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
    Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.
    Heutling D; Schulz H; Nickel I; Kleinstein J; Kaltwasser P; Westphal S; Mittermayer F; Wolzt M; Krzyzanowska K; Randeva H; Schernthaner G; Lehnert H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):82-90. PubMed ID: 17986642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Sahin Y; Bayram F
    Eur J Endocrinol; 1999 Jan; 140(1):56-61. PubMed ID: 10037253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial.
    Zhao H; Zhang J; Xing C; Cheng X; He B
    J Ovarian Res; 2024 Feb; 17(1):42. PubMed ID: 38374053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
    Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C; Wior M; Iraci GS; Kaplan R; Torres D; Gaido MI; Wyse EP
    Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
    Sönmez AS; Yasar L; Savan K; Koç S; Ozcan J; Toklar A; Yazicioğu F; Akgün A; Sut N
    Hum Reprod; 2005 Jan; 20(1):175-9. PubMed ID: 15513975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.